Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
Clinical Lung Cancer(2020)
摘要
Although gefitinib, erlotinib, and afatinib showed a comparable TTP in patients receiving first-line therapy, the incidence of T790M differed among them, as demonstrated by the present study, which could have implications for the choice of second-line treatment.
更多查看译文
关键词
Drug resistance,EGFR,Mutation,Non-squamous non-small cell lung cancer,Tyrosine kinase inhibitors
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络